LACTB and Pseudomonas infection: This raises the possibility of using this structural information in the design of new nonlactam inhibitors which would not be susceptible to degradation by beta‐lactamases and hence overcome at least one mechanism of antibiotic resistance in the treatment of Pseudomonas infections.